Filtered By:
Condition: Thrombosis
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 862 results found since Jan 2013.
Contemporary Analysis of Incidence and Outcomes of Stent Thrombosis Presenting as ST Elevation Myocardial Infarction in a Primary Percutaneous Coronary Intervention Cohort
There are limited data about the effectiveness of primary percutaneous coronary intervention (PPCI) for stent thrombosis treatment. We aimed to evaluate the prevalence and outcomes of PPCI in patients with ST elevation acute myocardial infarction (STEMI) due to stent thrombosis, and comparing the outcomes with patients treated for de novo coronary thrombosis. This was an observational cohort study of 2,935 patients who underwent PPCI from 2003 to 2011 with follow-up for a median of 3.0 years (interquartile range 1.2 to 4.6). The primary end point was the first major adverse cardiac event (MACE) defined as death, nonfatal ...
Source: The American Journal of Cardiology - September 9, 2013 Category: Cardiology Authors: Daniel A. Jones, Sean Gallagher, Krishnaraj S. Rathod, Mohammed Akhtar, Charles J. Knight, Martin T. Rothman, Akhil Kapur, Anthony Mathur, Ajay K. Jain, Adam D. Timmis, Elliot J. Smith, Andrew Wragg Tags: Coronary Artery Disease Source Type: research
Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction.
CONCLUSIONS: The early safety and efficacy of the MGuard stent was maintained during the long-term follow-up. However, comparative data from ongoing randomized clinical trials are still required to confirm the long-term efficacy of the MGuard stent implantation in patients with STEMI.
PMID: 24142749 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - October 21, 2013 Category: Cardiology Authors: Dudek D, Dziewierz A, Kleczyński P, Giszterowicz D, Rakowski T, Sorysz D, Rzeszutko L, Legutko J, Bartuś S, Dragan J, Klecha A, Siudak Z, Zmudka K Tags: Kardiol Pol Source Type: research
Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry
ConclusionsIn this large, real‐world population of AF patients undergoing PCI‐S, TT was the antithrombotic regimen most frequently prescribed. Although several limitations need to be acknowledged, in our study the 1‐year efficacy and safety of TT, dual antiplatelet therapy, and VKA plus clopidogrel was comparable.
Source: Clinical Cardiology - January 30, 2014 Category: Cardiology Authors: Andrea Rubboli, Axel Schlitt, Tuomas Kiviniemi, Fausto Biancari, Pasi P. Karjalainen, Josè Valencia, Mika Laine, Paulus Kirchhof, Matti Niemelä, Saila Vikman, Gregory Y. H. Lip, K. E. Juhani Airaksinen, Tags: Clinical Investigations Source Type: research
Towards Effective and Safe Thrombolysis and Thromboprophylaxis: Preclinical Testing of a Novel Antibody-Targeted Recombinant Plasminogen Activator Directed Against Activated Platelets.
CONCLUSIONS: Targeting of scuPA to activated GPIIb/IIIa allows effective thrombolysis and the potential novel use as a fibrinolytic agent for thromboprophylaxis without bleeding complications.
PMID: 24508759 [PubMed - as supplied by publisher]
Source: Circulation Research - February 9, 2014 Category: Cardiology Authors: Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE Tags: Circ Res Source Type: research
Impact of Obstructive Sleep Apnea on Cardiovascular Outcomes in Patients Treated With Percutaneous Coronary Intervention: Rationale and Design of the Sleep and Stent Study
ABSTRACT
Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes is crucial in risk assessments and therapeutic recommendations for affected individuals. The Sleep and Stent Study is a multicenter observational study investigating the relationships between OSA and cardiovascular outcomes in patients treated with percutaneous coronary intervention (PCI). Eight centers in 5 countries (Singapore, China and Hong Kong, India, Myanmar, and Brazil) are participating in the study, and the recruitment target is 1600 patients. Adult patients age 18 to 80 years who have undergone successful PCI are eligibl...
Source: Clinical Cardiology - February 22, 2014 Category: Cardiology Authors: Germaine Loo, Chieh‐Yang Koo, Junjie Zhang, Ruogu Li, Rithi Sethi, Thun‐How Ong, Bee‐Choo Tai, Chi‐Hang Lee Tags: Trial Designs Source Type: research
CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention
Conclusions: High CHA2DS2-VASc score was the best predictor of thrombotic outcomes after PCI in a high risk AF population. High mHAS-BLED score was not predictive of bleeding events. More accurate, simple risk scores are needed.
Source: Thrombosis Research - January 24, 2014 Category: Hematology Authors: Marja K. Puurunen, Tuomas Kiviniemi, Axel Schlitt, Andrea Rubboli, Britta Dietrich, Pasi Karjalainen, Kai Nyman, Matti Niemelä, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Clinical Studies Source Type: research
Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial
ConclusionsIn patients with ACS, ticagrelor significantly reduced the incidence of MI compared with clopidogrel, with consistent results across most MI subtypes. CEC procedures identified more MI endpoints compared with site investigators. (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome [PLATO]; NCT00391872)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - April 14, 2014 Category: Radiology Source Type: research
Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population
Conclusion: Among Korean population undergoing contemporary PCI, women have a significantly higher risk of short- and long-term major cardiovascular events than do men but have better long-term survival.
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park Tags: Interventional Cardiology Source Type: research
Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary Intervention
Atherosclerosis and venous thromboembolism (VTE) share common risk factors. We set to assess the strength of the association between atherosclerosis risk factors and disease manifestation, and VTE, in patients with coronary artery disease undergoing percutaneous coronary intervention. We pooled data from 6 global randomized controlled trials assessing coronary stenting (ENDEAVOR and SIRIUS programs), developed separate risk scores to predict major adverse cardiac and cerebrovascular events (MACCEs: cardiac death, myocardial infarction, and stroke) and VTE, and compared their performance. The 5-year rates of MACCE and VTE w...
Source: Clinical and Applied Thrombosis/Hemostasis - May 26, 2014 Category: Hematology Authors: Vardi, M., Piazza, G., Pencina, M. J., Burke, D. A., Lei, L., Goldhaber, S. Z., Cutlip, D. E. Tags: Original Articles Source Type: research
CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Conclusion: The POPular Genetics study is the first large-scale trial comparing CYP2C19 genotype–guided antiplatelet therapy to a nontailored strategy in terms of net clinical benefit, safety, and cost-effectiveness.
Source: American Heart Journal - March 24, 2014 Category: Cardiology Authors: Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper, Khalid Qaderdan, Maycel Ishak, Rianne S. Ruitenbeek, Folkert W. Asselbergs, Arnoud W.J. van ‘t Hof, Willem J.M. Dewilde, Fabrizio Spanó, Jean-Paul R. Herrman, Johannes C. Kelder, Maarten J. P Tags: Trial Design Source Type: research
Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry.
Conclusions: Bivalirudin usage in the setting of primary PCI provided excellent results in terms of 30-day outcome even in a real-world population.
PMID: 25101656 [PubMed - as supplied by publisher]
Source: Acute Cardiac Care - August 7, 2014 Category: Cardiology Authors: Limbruno U, Picchi A, Galli S, Huber K, Lipiecki J, Bernstein D, Deliargyris E, Anthopoulos P, Nienaber C, Hamon M Tags: Acute Card Care Source Type: research
The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
In conclusion, the magnitude of platelet reactivity as well as the incidence of HPR was higher in patients with CKD. However, since the incidence of HPR was similar after adjustment, a higher rate of co-morbidities in patients with CKD might be the major cause for this observation rather than CKD itself. CKD-patients with HCPR were at the highest risk of long-term cardiovascular events.
PMID: 25231776 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 18, 2014 Category: Hematology Authors: Breet NJ, de Jong C, Bos WJ, van Werkum JW, Bouman HJ, Kelder JC, Bergmeijer TO, Zijlstra F, Hackeng CM, Ten Berg JM Tags: Thromb Haemost Source Type: research
Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity
Conclusion
An LVEF <35 % was found to be independently associated with HCPR.
Source: American Journal of Cardiovascular Drugs - August 1, 2014 Category: Cardiology Source Type: research
Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity
Abstract
High on-treatment platelet reactivity (HTPR) on clopidogrel correlates with adverse outcomes in patients treated with percutaneous coronary intervention (PCI). Whether HTPR is a modifiable risk factor for future events is not clear. We evaluated the effect of serial clopidogrel dose adjustment based on platelet function testing (PFT) during 12 months of dual antiplatelet therapy (DAPT) using Multiplate® analyzer in patients with HTPR after PCI in acute coronary syndrome on clinical outcome. Eighty-seven patients were randomized to interventional (n = 43) and control group (n = 44). Blood samples fo...
Source: Journal of Thrombosis and Thrombolysis - October 2, 2014 Category: Hematology Source Type: research
